• Dermatol Surg · Mar 2004

    Clinical Trial

    Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.

    • Amy Huber, John D Huber, Robert B Skinner, Raymond T Kuwahara, Raashid Haque, and Rex A Amonette.
    • Department of Medicine, Division of Dermatology, University of Tennessee, Memphis, USA.
    • Dermatol Surg. 2004 Mar 1; 30 (3): 429-30.

    BackgroundImiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.ObjectiveTo evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.ResultsAfter 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.ConclusionImiquimod 5% cream may be another treatment modality for nodular BCC.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.